Damon Runyon Researchers

Meet Our Scientists
Alexander C. Huang, MD

Immune checkpoint inhibitors (ICI), like anti-PD-1 therapy (αPD-1), have transformed clinical oncology by inducing long-term remissions, even in metastatic disease. However, fewer than 40% of cancer patients achieve such long-term remission with αPD-1, and immune-related toxicity limits more aggressive combined approaches, such as anti-PD1 and anti-CTLA-4 therapy. The question remains why a large portion of the immune response generated by combination immunotherapy is directed towards toxicity rather than anti-tumor immunity. A better understanding of the T-cell response to ICI is needed to develop safer and more effective treatment strategies. In humans, CD8+ T-cells are responsible for anti-tumor immunity. Dr. Huang is investigating the immune responses of different types of CD8+ T-cells to αPD-1 and whether they play a role in determining clinical efficacy and immune toxicity.

Project title: "Shared antigen and neoantigen-specific T cells in checkpoint blockade efficacy and toxicity"
Institution: University of Pennsylvania
Named Award: Damon Runyon-Doris Duke Clinical Investigator
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): Gerald P. Linette, MD, PhD
Cancer Type: Skin
Research Area: Immunotherapy